Inhibitors of bruton's tyrosine kinase

A compound of Formula (IA) having the structure:

• wherein:
• ring A is substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted C6-C12aryl, or substituted or unsubstituted C1-C12heteroaryl;
• W is —C(R2)— or —N—;
• X is —C(R2)— or —N—;
• Y is optionally present and when present is —CH2O—, —OCH2—, —OCH2CH2O—, —O—, —N(R3)—, —C(O)—, —N(R3)C(O)—, —C(O)N(R3)—, —N(R3)C(O)N(R3)—, —S(O)—, —S(O)2—, —N(R3)S(O)2—, —S(O)2N(R3)—, —C(═NH)—, —C(═NH)N(R3)—, —C(═NH)N(R3)—, or substituted or unsubstituted C1-C4alkylene;
• Z is optionally present and when present is substituted or unsubstituted C1-C3alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted C6-C12aryl, or substituted or unsubstituted C1-C12heteroaryl;
• G is
• R1 is —R4, —CH2R4, —C(O)R9, —C(O)C(O)R9, —C(O)OR4, —C(O)N(R3)(R4), or —S(O)2R9;
• R1′ is —C(O)R9′, —C(O)C(O)R9, —C(O)OR4, —C(O)N(R3)(R4), or —S(O)2R9;
• each R2 is independently H, substituted or unsubstituted C1-C4alkyl, —CN, or halogen;
• each R3 is independently is H, or substituted or unsubstituted C1-C4alkyl;
• each R4 is independently H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted C6-C12aryl, or substituted or unsubstituted C1-C12heteroaryl;
• R5 is H, substituted or unsubstituted C1-C4alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted C6-C12aryl, or substituted or unsubstituted C1-C12heteroaryl;
• or R1 and R5 together with the nitrogen atom to which they are attached are combined to form a substituted or unsubstituted C2-C9heterocycloalkyl ring;
• each R6 is independently halogen, —CN, —OH, —NH2, substituted or unsubstituted C1-C4alkoxy, substituted or unsubstituted C1-C4alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-C6heterocycloalkyl, or —N(R3)2;
• or R1 and R6 are combined to form a substituted or unsubstituted C2-C9heterocycloalkyl ring;
• each R7 is independently halogen, —CN, —OH, —NH2, substituted or unsubstituted C1-C4alkoxy, substituted or unsubstituted C1-C4alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C2-C6heterocycloalkyl, or —N(R3)2;
• R9 is —R4, or
• R10 is H, halogen, —CN, or -L1-L2;
• R11 and R12 are independently H, halogen, —CN, or -L1-L2;
• or R11 and R12 taken together form a bond;
• each L1 is optionally present and when present each L1 is independently substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted C6-C12aryl, substituted or unsubstituted C1-C12heteroaryl, —C(═O)—, —O—, or —S—;
• each L2 is independently H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C3-C6cycloalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted C6-C12aryl, substituted or unsubstituted C1-C12heteroaryl or —N(R13)2;
• each R13 is independently H, C1-C6alkyl, C3-C6cycloalkyl, C1-C6heteroalkyl, C2-C7 heterocycloalkyl, C6-C12aryl, or C1-C12heteroaryl;
• n is 0-3;
• p is 0-3;
• and
• q is 0-3;
• or a pharmaceutically acceptable solvate, pharmaceutically acceptable salt, or pharmaceutically acceptable prodrug thereof;
• provided that
• i) when W is N, and R1 is H, t-Boc, or —C(O)—CH═CH2;
• then X is other than C-Et or N;
• and
• ii) when W is N, G is
• then X is CH or N;
• iii) when W is N, and X is CH;
• then R1′ is other than —C(O)Me, or t-Boc;
• and
• iv) when n is 0;
• then each of p and q is independently 0, 1, or 2.